Method based on surgery * Orchiectomy (surgical castration) :It consists of removing the testicles, the organ where<unk> s are synthesized, of the cancer sufferers. It is the most radical treatment for ending the production of<unk> s. Moreover it is the easiest and least expensive one. The main disadvantage is that surgical castration is a permanent method. Methods based on drugs Testosterone synthesizing process * Chemical castration :The synthesis of testosterone is mediated by a chain of processes that start in the brain. When the body detects a low level of testosterone, the hypothalamus starts to produce LHRH. LHRH activates the synthesis of LH (Luteinizing hormone) within the pituitary gland. LH induces testosterone synthesis within the testicles. There are two different medicines, LHRH agonists and antagonists, which both lower the amount of testosterone made by the testicles. They work by inhibiting the formation of LH in the pituitary gland. The LHRH agonists produce a sudden increase on levels of testosterone followed by a huge falling, process called flare, whereas LHRH antagonists decrease directly the amount of testosterone. LHRH agonists and antagonists used in<unk>  include leuprorelin (leuprolide), goserelin, triptorelin, histrelin, buserelin, and degarelix. :These drugs are injected under the skin achieving the same result as surgical castration. Chemical castration may be preferred to surgical castration as it keeps the testes intact. * Antiandrogen therapy :Adrenal glands were discovered as another center of<unk>  production even after a castration process. Therefore a complementary treatment was developed that uses antiandrogens to block the body’s ability to use any<unk> s. Prostate cells contain an<unk>  Receptor (AR), that when stimulated by<unk> s like testosterone, promotes growth and maintains prostatic differentiation. These pro-growth signals, however, can be problematic when they occur in a cancer cell. Antiandrogens can enter cells and prevent the binding of testosterone to the receptor proteins, due to their higher affinity for the<unk>  Receptor. :The main antiandrogens are cyproterone acetate, flutamide, nilutamide, bicalutamide, and enzalutamide which are all administered in oral pill form. :New antiandrogens that target testosterone synthesis (abiraterone acetate and seviteronel) or AR nuclear translocation (enzalutamide, apalutamide, and darolutamide), as well as combined therapies (galeterone) have been recently developed and may function to better target<unk> -responsive cells in combination with<unk> . But these too may have negative adverse roles in the development of CRPC.
Androgen deprivation therapy
Estrogen deprivation therapy
Hormone therapy
Masculinizing hormone therapy
Feminizing hormone therapy
Androgen replacement therapy
Hormonal therapy 
Prostate brachytherapy